Journal of Ovarian Research最新文献

{"title":"Impact of surgical modalities on the survival of stage I adult-type ovarian granulosa cell tumor: a comprehensive analysis of 101 cases.","authors":"Qingna Chen, Lili Liu, Jiaqi Qiu, Huijuan He, Hua Tu, Haifeng Gu","doi":"10.1186/s13048-025-01806-z","DOIUrl":"10.1186/s13048-025-01806-z","url":null,"abstract":"<p><strong>Background: </strong>Only small-sample retrospective studies have been performed to assess the efficacy of current treatment modalities for adult-type ovarian granulosa cell tumor. Therefore, we retrospectively evaluated patients with stage I AGCT admitted to our center over the past two decades and systematically analyzed the impact of different surgical modalities on the survival of these patients.</p><p><strong>Methods: </strong>All patients with stage I AGCT treated in Sun Yat-sen University Cancer Center from May 1998 to April 2020 were enrolled and analyzed in this retrospective study.</p><p><strong>Results: </strong>A total of 101 patients with stage I AGCT were identified, among whom 49 were stage Ia and 52 were stage Ic. The median follow up was 47.7 months. The 10-year cancer specific survival (CSS) and disease-free survival (DFS) rates were 90% and 53%, respectively. Multivariate analysis showed that only surgical extent (conservative vs. radical, HR: 2.738, p-value = 0.034) was an independent prognostic factor for disease-free survival. Subgroup analysis suggested that both surgical extent and surgical approach had a significant impact on the disease-free survival of patients with stage Ic (conservative vs. radical, HR: 4.021, p-value = 0.007; laparoscopic vs. open, HR: 2.926, p-value = 0.035) and tumor larger than 5 cm (conservative vs. radical, HR: 4.437, p-value = 0.001; laparoscopic vs. open, HR: 3.367, p-value = 0.006).</p><p><strong>Conclusions: </strong>Patients with stage I AGCT generally have a favorable prognosis. Surgical extent is an independent prognostic factor. For high risk patients with stage Ic disease or tumor larger than 5 cm, our study supports the selection of radical and open surgery as a potentially preferred option.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"212"},"PeriodicalIF":4.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research on the process and molecular mechanism of inhibiting serous ovarian cancer by PRTN3 and its inhibitor Sivelestat.","authors":"Changtao Zheng, Luzhu Chen, Xiaotian Lv, Yaoyao He, Xiangyun Hu, Ying Ding, Sheng Wang, Peng Wei, Tao Zhang, Huainian Zhang, Xiaoting Zhang, Yongli Zhang","doi":"10.1186/s13048-025-01808-x","DOIUrl":"10.1186/s13048-025-01808-x","url":null,"abstract":"<p><strong>Background: </strong>Serous ovarian cancer (SOC) is one of the most important diseases affecting women's health in the world. It is highly occult and often detected in late stage due to the lack of specific molecular markers.</p><p><strong>Methods: </strong>Whole exon sequencing was performed on 38 serous ovarian cancer samples, and the mutated gene PRTN3 was selected by bioinformatics analysis. In vitro experiments with serous ovarian cancer cell lines SKOV3 and OVCAR8 and normal ovarian epithelial cell line IOSE80 were performed to verify the expression of PRTN3 and the effect of its inhibitor sivelestat. Xenotransplantation models in vivo also confirmed the effect of sivelestat.</p><p><strong>Result: </strong>We found that Missense Mutation accounted for the vast majority of somatic mutations, and 263 candidate mutant genes were obtained from the mutation frequency, among which three hub gene clusters centered on SF3A2, MUC3A, and PRTN3 were identified, and PRTN3 had the strongest effect on the overall survival of the patients. Subsequently, we verified the expression of PRTN3 in serous ovarian cancer samples and cell lines, PRTN3 was highly expressed in serous ovarian cancer samples and cell lines, and sivelestat could inhibit the migration ability of serous ovarian cancer cell lines. SKOV3 cells were used to construct xenografted tumor models to explore the prospect of PRTN3 as a molecular therapeutic target for ovarian cancer and the application potential of sivelestat, which can inhibit the progression of xenografted tumors in vivo with certain safety.</p><p><strong>Conclusions: </strong>Whole exome sequencing and bioinformatics analysis identified PRTN3 as a potential molecular marker of serous ovarian cancer, and PRTN3 could significantly affect the prognosis of SOC patients. As an inhibitor of PRTN3, sivelestat can inhibit the expression of PRTN3 in SOC cell lines and reduce their migration ability in vitro. In vivo experiments showed that sivelestat can inhibit the growth of subcutaneous transplanted tumor in nude mice with certain safety.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"211"},"PeriodicalIF":4.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PTX3 as a key modulator of functional ovarian response in PCOS: evaluation alongside TSG-6 and ITI.","authors":"Zercan Kalı, Ümran Karabulut, Tuba Memur, Fatma Tanılır Çağıran, Nihal Mavral, Pınar Kırıcı","doi":"10.1186/s13048-025-01798-w","DOIUrl":"10.1186/s13048-025-01798-w","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the relationship between follicular fluid pentraxin 3 (PTX-3) levels and ovarian response, embryo quality, and insulin resistance (IR) in patients with polycystic ovary syndrome (PCOS) undergoing IVF/ICSI.</p><p><strong>Methods: </strong>A total of 130 women were enrolled and categorized into three groups: lean PCOS (n = 43), overweight PCOS (n = 42), and unexplained infertility (UEI, n = 45). Patients with endocrine disorders, chronic inflammatory diseases, or recent hormonal therapy (within 3 months) were excluded. Follicular fluid (FF) and serum PTX-3 levels were measured using ELISA. Subgroup analyses were performed according to BMI and HOMA-IR status. Correlations between FF PTX-3 and clinical, hormonal, and embryological parameters were assessed. ROC curve analysis and multivariate linear regression were used to evaluate the diagnostic and predictive value of FF biomarkers for follicular output rate (FORT).</p><p><strong>Results: </strong>FF PTX-3 levels were significantly higher in both lean (23.31 ± 1.33 ng/mL) and overweight PCOS patients (12.54 ± 1.05 ng/mL) compared to UEI controls (7.01 ± 0.54 ng/mL; p = 0.029). Notably, PTX-3 remained elevated in lean PCOS despite a lower BMI, supporting its role in intrinsic ovarian inflammation. FF PTX-3 showed significant positive correlations with total testosterone (r = 0.580), AFC (r = 0.598), and oocyte count (r = 0.532), but was inversely associated with high-quality embryo number (r = - 0.482), 2PN count (r = - 0.312), and FORT (r = - 0.418). ROC analysis demonstrated moderate diagnostic performance of PTX-3 for predicting suboptimal FORT (AUC = 0.77; cut-off: 20.4 ng/mL). In multivariate analysis, FF PTX-3 (β = - 0.65, p = 0.001), TSG-6 (β = - 0.42), and ITI (β = - 0.37) were independent negative predictors of FORT, while AFC was positively associated.</p><p><strong>Conclusion: </strong>Elevated follicular PTX-3 levels are linked to hyperandrogenism and ovarian reserve in PCOS, but may impair embryo quality and functional follicular response. PTX-3 may serve as a potential biomarker of ovarian inflammation and compromised oocyte competence, independent of BMI or systemic insulin resistance.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"204"},"PeriodicalIF":4.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145176098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of Zuogui pill in the treatment of polycystic ovary syndrome based on LC-MS and proteomics.","authors":"Yuxuan Ke, Yiting Tang, Jiajing He, Min Xiao, Min Zhao","doi":"10.1186/s13048-025-01802-3","DOIUrl":"10.1186/s13048-025-01802-3","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder that severely impairs female fertility. Zuogui pill (ZGP) is clinically used for the treatment of reproductive disorders such as menopause syndrome and premature ovarian failure, improving female reproductive health. However, the mechanism of its action in treating PCOS remains unclear. This study aimed to investigate the mechanism of ZGP in treating PCOS based on liquid chromatography-mass spectrometry (LC-MS) and proteomics.</p><p><strong>Methods: </strong>LC-MS was utilized to analyze and identify the active components of ZGP. A PCOS rat model was established using a high-fat diet combined with letrozole to assess the efficacy of ZGP. Serum hormone levels in rats were detected using ELISA, and ovarian morphology was examined via hematoxylin and eosin staining. 4D-DIA-based proteomics was performed on ovarian samples from rats, and a combined analysis with network pharmacology was conducted to identify key pathways and their targets. Finally, Western blot analysis was used to validate the analytical results.</p><p><strong>Results: </strong>A total of 31 components of ZGP were identified through LC-MS analysis combined with the TCMSP database. In the PCOS rat model, ZGP significantly improved obesity and ovarian tissue damage, regulated serum sex hormone secretion levels. Through a combined analysis of network pharmacology and 4D-DIA-based proteomics, the potential mechanism of ZGP in improving PCOS was determined to be the mitogen-activated protein kinase (MAPK) signaling pathway. WB analysis revealed that ZGP reversed the expression levels of p-ERK1/2 and p-JNK.</p><p><strong>Conclusion: </strong>This study demonstrates that ZGP may exert a therapeutic effect on PCOS through the MAPK signaling pathway.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"205"},"PeriodicalIF":4.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145176166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PARPis after PARPis in patients with recurrent epithelial ovarian cancer: a single institutional experience.","authors":"Hua Yuan, Tonghui Wang, Hongwen Yao, Lingying Wu, Ning Li","doi":"10.1186/s13048-025-01786-0","DOIUrl":"10.1186/s13048-025-01786-0","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical efficacy of PARPis maintenance treatment rechallenge in patients with recurrent epithelial ovarian cancer (EOC) in China.</p><p><strong>Methods: </strong>We included patients diagnosed with primary EOC who received 2 lines of PARPis maintenance treatment after achieving complete response (CR) or partial response (PR) with the previous chemotherapies. The patients' full medical records were included in this study. Clinical and pathologic variables, treatment modalities, and outcomes were assessed. We investigated the treatment patterns and time to next treatment (TTNT).</p><p><strong>Results: </strong>A total of 31 ovarian cancer patients in our center were included. Among these patients, 20 of them (64.5%) had BRCA1/2 gene mutations. The median duration of PARPi1 and PARPi2 in the entire cohort was 11.2 months (range: 2.0-30.4 months) and 4.8 months (range: 1.0-16.7 months), respectively. Median TTNT1 and TTNT2 for the entire cohort was 12.4 and 7.7 months, respectively. Patients with BRCA1/2 mutation had a significantly better TTNT1 (median TTNT1: 17.3 vs 10.4 months, P = 0.005) than those without. A non- significantly better TTNT2 was observed in patients with BRCA1/2 mutation than those without (median TTNT2: 8.2 vs 5.0 months, P = 0.890). The association between previous chemotherapy response and TTNT was also analyzed. Patients who had a CR to previous chemotherapy had a significantly better TTNT1 (median TTNT1: 16.4 vs 7.6 months, P = 0.001) and TTNT2 (median TTNT2: 11.1 vs 4.9 months, P = 0.003) than those who had a PR. No grade Ⅲ-IV anemia occurred. Grade III PARPis-related thrombocytopenia was found in only 1 patient (3.2%, 1/31) who received PARPi2 treatment. For patients who developed PARPis-related anemia (n = 9) or thrombocytopenia (n = 7) during PARPi1 treatment, 7 patients (77.8%, 7/9) and 6 patients (85.7%, 6/7) developed anemia or thrombocytopenia again during PARPi2 treatment, respectively.</p><p><strong>Conclusions: </strong>Patients with PARPis resistant recurrent EOC may derive benefit from PARPis re-treatment, especially for those with complete response to the last chemotherapy. Patients with BRCA1/2 mutation were more likely to benefit from PARPis retreatment than those with wild-type. Anemia and thrombocytopenia were more common in PARPis retreatment patients. A small proportion of patients had a longer benefit from PARPis retreatment than from previous PARPis treatment.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"206"},"PeriodicalIF":4.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145176127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autophagy in ovary: protective roles, pathological consequences, and unresolved issues.","authors":"Xianan Tang, Xiaofan Gao, Tong Wu, Shixuan Wang, Yueyue Gao, Jinjin Zhang","doi":"10.1186/s13048-025-01784-2","DOIUrl":"10.1186/s13048-025-01784-2","url":null,"abstract":"<p><p>The ovaries play essential roles in providing oocytes for fertilization and secreting sex hormones that regulate various organ functions. Autophagy has been implicated in the modulation of ovarian functions, yet its mechanisms of action are complex and context-dependent. Within the ovary, autophagy fulfills a dual function, serving as a critical mechanism in facilitating oocyte development, maintaining granulosa cell viability, regulating hormone synthesis, ovulation and luteal function. Conversely, dysregulation of autophagy can interact with other death signals, leading to cell death of ovarian cells, and has been linked to the development of diminished ovarian reserve (DOR), premature ovarian insufficiency (POI) and polycystic ovary syndrome (PCOS). Emerging evidence suggests that pharmacological modulation of autophagy exerts significant therapeutic effects on POI and PCOS. Despite this association, numerous unresolved issues persist in this field of research. This paper provides a comprehensive overview of the context-dependent roles of autophagy in ovarian physiology and disorders, and proposes potential applications of autophagy-based interventions as therapeutic strategies for addressing ovarian dysfunctions.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"202"},"PeriodicalIF":4.2,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diosmetin ameliorates inflammation and apoptosis in the pathomechanism of PCOS through the NRF2/AKT/PPARγ signalling pathway.","authors":"Mengting Chen, Jingwen Meng, Yafang Jin, Yu Chen, Yuan Liu, Xiong Yuan, Zhiquan Qin, Xiaohui Cao","doi":"10.1186/s13048-025-01788-y","DOIUrl":"10.1186/s13048-025-01788-y","url":null,"abstract":"<p><strong>Ethnopharmacological relevance: </strong>Diosmetin (DIO) is a flavonoid extracted from the traditional Chinese medicine Schizonepeta tenuifolia Briq. The anti-inflammatory and neuroprotective properties of DIO have shown promise. However, the underlying mechanisms need further elucidation.</p><p><strong>Study aim: </strong>This research aimed to explore how DIO reduces oxidative stress and inflammation in the ovaries and slows the pathological development of polycystic ovary syndrome by influencing the AKT/PPARγ signalling pathway.</p><p><strong>Materials and methods: </strong>DIO targets were screened via network pharmacology tools. The protective effect of DIO on polycystic ovary syndrome was assessed via haematoxylin‒eosin (H&E) staining. Immunohistochemical staining, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence were used to determine the effects of DIO on ovarian granulosa cell inflammation. In addition, we performed Western blotting to determine the expression of TNF-α, IL-6 and AKT/PPARγ pathway proteins.</p><p><strong>Results: </strong>This research demonstrated an increase in TNF-α and IL-6 expression in a rat model of polycystic ovary syndrome (PCOS) induced by letrozole. Histological analysis indicated that the ovaries of rats in the PCOS group showed significant follicular loss and vacuolation changes compared with those in the normal control (NC) group. Treatment with DIO improved the cystic changes in the ovaries. Metabolic assessments revealed that the PCOS group presented significantly altered levels of FSH (4.2 ± 0.3 IU/L), TG (0.65 ± 0.2 mmol/L), E2 (106 ± 14 pg/L), TC (3.9 ± 0.7 mmol/L), LH (7.8 ± 0.2 IU/L), and TEST (11 ± 3 ng/mL) compared with those in the NC group (FSH: 6.3 ± 1.7 IU/L; TG: 1.2 ± 0.2 mmol/L; E2: 147 ± 21 pg/mL; TC: 2.2 ± 0.4 mmol/L; LH: 5.8 ± 1.2 IU/L; and TEST: 5.5 ± 2 ng/mL), indicating hyperandrogenaemia. Additionally, at the conclusion of the study, the PCOS group (310 ± 7 g) presented a significant increase in body weight compared with the NC group (310 ± 7 g), whereas treatment with 50 mg/kg DIO (351 ± 6 g) or 100 mg/kg DIO (342 ± 8 g) mitigated this weight gain. Immunohistochemistry, Western blot, and immunofluorescence results revealed that DIO reduced inflammation and alleviated the pathological changes associated with PCOS. Furthermore, DIO improved the inflammatory condition of the ovaries in the PCOS group by inhibiting the AKT/PPARγ signalling pathway. The suppression of AKT and PPARγ diminished the anti-inflammatory effects of DIO. Additionally, DIO countered inflammation and apoptosis in testosterone-induced ovarian granulosa cells by enhancing the expression of AKT/PPARγ signalling.</p><p><strong>Conclusion: </strong>The present study confirms that DIO has important therapeutic potential for treating polycystic ovary syndrome by inhibiting ovarian inflammation and oxidative stress through the modulation of AKT/PPARγ signalling.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"203"},"PeriodicalIF":4.2,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of the mechanism of PCOS induced by microenvironmental changes in follicular fluid based on 16 S rRNA and metabolomics.","authors":"Cong Wang, Huimin Zhao, Andriy Sibirny, Weihua Pan, Rubing Liang, Gang Luo, Gongyou Zhang, Yanyan Wang, Yingqian Kang","doi":"10.1186/s13048-025-01781-5","DOIUrl":"10.1186/s13048-025-01781-5","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder in women of childbearing age. The follicular microenvironment plays a vital role in oocyte development as one of the important factors affecting PCOS. This study aimed to reveal the changes in the follicular microenvironment of PCOS rats using multi-omics analysis.</p><p><strong>Methods: </strong>A PCOS rat model was constructed using dehydroepiandrosterone (DHEA) method, and 16 S rRNA amplicon sequencing and non-targeted metabolomics were applied to analyze the follicular fluid samples from the control and the PCOS groups. The key microbiota were screened using T-test analysis, and the key metabolites were identified through Spearman correlation hierarchical cluster analysis. Bioinformatics and network pharmacology were used to identify overlapping genes between the key metabolite targets and PCOS-related targets, followed by Gene Ontology (GO) classification and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.</p><p><strong>Results: </strong>There were significant differences in the microbiome composition between the two groups, with a general decrease in the microbial abundance in the follicular fluid of the PCOS group compared to the control group. T-test analysis identified Acinetobacter haemolyticus as a significantly different strain. Spearman correlation analysis exhibited a positive correlation between Acinetobacter haemolyticus and three metabolites (S-adenosylmethioninamine, prorocentrolide, and cilostazol). Network pharmacology and bioinformatics analyses revealed that the overlapping genes of these metabolites targets and PCOS-related targets were enriched in autophagy-related signaling pathways, with cilostazol as a candidate metabolite and SRC as a potential target. Additionally, Liquid Chromatography-Mass Spectrometry (LC-MS) analysis confirmed the presence of Acinetobacter haemolyticus in the follicular fluid of rats and its ability to metabolize cilostazol.</p><p><strong>Conclusions: </strong>Cilostazol is a significantly differentiated metabolite in the follicular microenvironment of PCOS rats, playing a role in PCOS development by regulating autophagy-related signaling processes mediated by SRC.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"201"},"PeriodicalIF":4.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperandrogenism in polycystic ovary syndrome augments Estrogen synthesis through AR-FOXL2-mediated activation of the aromatase gene in granulosa cells.","authors":"Yi-Ru Tsai, Yen-Nung Liao, Cheng-Ju Tsai, Yu-Ang Lee, Shih-Min Hsia, Kuo-Chung Lan, Hong-Yo Kang","doi":"10.1186/s13048-025-01790-4","DOIUrl":"10.1186/s13048-025-01790-4","url":null,"abstract":"","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"200"},"PeriodicalIF":4.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homozygous variant in JARID2 causes female infertility characterized by compromised blastulation efficiency.","authors":"Jiaqi Sun, Huiling Hu, Fei Meng, Pingyuan Xie, Fei Gong, Ge Lin, Jing Dai, Wei Zheng","doi":"10.1186/s13048-025-01783-3","DOIUrl":"https://doi.org/10.1186/s13048-025-01783-3","url":null,"abstract":"<p><strong>Background: </strong>Impaired embryonic developmental competence is a critical determinant of assisted reproductive technology (ART) failure, yet current genetic diagnostics primarily address complete early embryonic arrest, leaving partial developmental defects unexplained, such as compromised blastulation efficiency (CBE). Jumonji and AT-rich interaction domain containing 2 (JARID2), encoding a chromatin-modifying factor essential for histone methylation regulation, emerges as a novel candidate in this context.</p><p><strong>Results: </strong>We identified a homozygous JARID2 missense variant (c.899G > A, p.Arg300Gln) in a female patient exhibiting CBE under autosomal recessive inheritance. Functional studies in transiently transfected HeLa cells demonstrated preserved protein abundance and subcellular localization but significantly attenuated ERK1/2 pathway activation. Microinjection of mutant mRNA into mouse zygotes recapitulated the CBE phenotype, accompanied by diminished histone H3K27me3 levels at the 2-cell stage. Comparative transcriptomic profiling revealed conserved transcriptional alterations in both patient-derived oocytes and murine embryos, marked by downregulation of genes critical for oogenesis, maternal-to-zygotic transition, and preimplantation development.</p><p><strong>Conclusions: </strong>These findings establish JARID2 as a maternal-effect gene governing early embryogenesis through epigenetic and ERK1/2-mediated regulatory axes, expanding the genetic diagnostic framework for ART failures and providing mechanistic insights into previously unexplained developmental defects.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"199"},"PeriodicalIF":4.2,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}